ATE458484T1 - ßVERFAHREN UND ZWISCHENPRODUKTE ZUR HERSTELLUNG VON STATINEN; INSBESONDERE VON ROSUVASTATINß - Google Patents
ßVERFAHREN UND ZWISCHENPRODUKTE ZUR HERSTELLUNG VON STATINEN; INSBESONDERE VON ROSUVASTATINßInfo
- Publication number
- ATE458484T1 ATE458484T1 AT05731809T AT05731809T ATE458484T1 AT E458484 T1 ATE458484 T1 AT E458484T1 AT 05731809 T AT05731809 T AT 05731809T AT 05731809 T AT05731809 T AT 05731809T AT E458484 T1 ATE458484 T1 AT E458484T1
- Authority
- AT
- Austria
- Prior art keywords
- formula
- compound
- group
- protecting
- protecting group
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 239000013067 intermediate product Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 13
- 125000006239 protecting group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000000640 hydroxylating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007142 ring opening reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0406757A GB0406757D0 (en) | 2004-03-26 | 2004-03-26 | Process and compounds |
| PCT/GB2005/001099 WO2005092867A2 (en) | 2004-03-26 | 2005-03-23 | Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE458484T1 true ATE458484T1 (de) | 2010-03-15 |
Family
ID=32188702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08157487T ATE536875T1 (de) | 2004-03-26 | 2005-03-23 | Verfahren und zwischenzusammensetzungen zur herstellung von statinen, insbesondere rosuvastatin |
| AT05731809T ATE458484T1 (de) | 2004-03-26 | 2005-03-23 | ßVERFAHREN UND ZWISCHENPRODUKTE ZUR HERSTELLUNG VON STATINEN; INSBESONDERE VON ROSUVASTATINß |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08157487T ATE536875T1 (de) | 2004-03-26 | 2005-03-23 | Verfahren und zwischenzusammensetzungen zur herstellung von statinen, insbesondere rosuvastatin |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8703945B2 (de) |
| EP (2) | EP1729775B1 (de) |
| JP (1) | JP5016478B2 (de) |
| KR (1) | KR20060130765A (de) |
| CN (1) | CN101022807B (de) |
| AT (2) | ATE536875T1 (de) |
| AU (1) | AU2005225602A1 (de) |
| BR (1) | BRPI0507999A (de) |
| CA (1) | CA2561059C (de) |
| CY (2) | CY1110091T1 (de) |
| DE (1) | DE602005019547D1 (de) |
| DK (2) | DK1729775T3 (de) |
| ES (2) | ES2379481T3 (de) |
| GB (1) | GB0406757D0 (de) |
| HR (1) | HRP20100287T1 (de) |
| IL (1) | IL178274A0 (de) |
| PL (2) | PL1958633T3 (de) |
| PT (2) | PT1958633E (de) |
| RS (1) | RS51306B (de) |
| SI (2) | SI1729775T1 (de) |
| WO (1) | WO2005092867A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002318041B2 (en) | 2001-07-13 | 2008-01-03 | Astrazeneca Uk Limited | Preparation of aminopyrimidine compounds |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| GB0406757D0 (en) * | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
| GB0427491D0 (en) * | 2004-12-16 | 2005-01-19 | Avecia Ltd | Process and compounds |
| WO2006136407A1 (en) * | 2005-06-24 | 2006-12-28 | Lek Pharmaceuticals D.D. | Process for preparing amorphous rosuvastatin calcium free of impurities |
| EP2134696B1 (de) | 2007-04-03 | 2017-05-17 | LEK Pharmaceuticals d.d. | Verfahren zur herstellung von statinen, insbesondere von rosuvastatin, und zwischenprodukt für deren herstellung |
| EP1978020A1 (de) * | 2007-04-03 | 2008-10-08 | LEK Pharmaceuticals D.D. | Verfahren zur Herstellung von Statinen, insbesondere von Rosuvastatin, und Zwischenprodukt für deren Herstellung |
| US8404870B2 (en) | 2008-01-23 | 2013-03-26 | Lek Pharmaceuticals D.D. | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof |
| GB0904100D0 (en) * | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of rosuvastatin lactols as medicaments |
| AU2013202895B2 (en) * | 2009-03-10 | 2014-09-18 | Redx Pharma Plc | Rosuvastatin and atorvastatin derivatives |
| GB0904104D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Atorvastatin and rosuvastatin derivatives |
| GB0904102D0 (en) * | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of atorvastatin lactols as medicaments |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474971A (en) * | 1982-09-29 | 1984-10-02 | Sandoz, Inc. | (Tetrahydropyran-2-yl)-aldehydes |
| US4625039A (en) * | 1983-12-21 | 1986-11-25 | Sandoz Pharm. Corp. | 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates |
| US4677211A (en) * | 1984-06-29 | 1987-06-30 | Sandoz Pharmaceuticals Corp. | Preparation of lactones |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US5795749A (en) | 1995-04-05 | 1998-08-18 | The Scripps Research Institution | Use of 2-deoxyribose-5-phosphate aldolase to prepare 2-deoxyfucose, analogues and derivatives |
| GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| WO2001022962A1 (en) * | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| GB0011163D0 (en) * | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
| WO2003026573A2 (en) * | 2001-09-24 | 2003-04-03 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
| DE10216967A1 (de) * | 2002-04-16 | 2003-11-13 | Bayer Ag | Verfahren zur Herstellung spezieller aromatischer Aldehyde |
| US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| EP1678148A1 (de) * | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Verfahren zur herstellung von amorphen rosuvastatin-calcium |
| DE10352659B4 (de) | 2003-11-11 | 2007-09-13 | Ratiopharm Gmbh | Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren |
| GB0406757D0 (en) * | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
-
2004
- 2004-03-26 GB GB0406757A patent/GB0406757D0/en not_active Ceased
-
2005
- 2005-03-23 DK DK05731809T patent/DK1729775T3/da active
- 2005-03-23 ES ES08157487T patent/ES2379481T3/es not_active Expired - Lifetime
- 2005-03-23 PT PT08157487T patent/PT1958633E/pt unknown
- 2005-03-23 AT AT08157487T patent/ATE536875T1/de active
- 2005-03-23 PT PT05731809T patent/PT1729775E/pt unknown
- 2005-03-23 AT AT05731809T patent/ATE458484T1/de active
- 2005-03-23 ES ES05731809T patent/ES2341658T3/es not_active Expired - Lifetime
- 2005-03-23 KR KR20067021900A patent/KR20060130765A/ko not_active Withdrawn
- 2005-03-23 US US10/594,380 patent/US8703945B2/en not_active Expired - Fee Related
- 2005-03-23 SI SI200531001T patent/SI1729775T1/sl unknown
- 2005-03-23 DE DE200560019547 patent/DE602005019547D1/de not_active Expired - Lifetime
- 2005-03-23 CA CA 2561059 patent/CA2561059C/en not_active Expired - Fee Related
- 2005-03-23 WO PCT/GB2005/001099 patent/WO2005092867A2/en not_active Ceased
- 2005-03-23 EP EP20050731809 patent/EP1729775B1/de not_active Expired - Lifetime
- 2005-03-23 SI SI200531491T patent/SI1958633T1/sl unknown
- 2005-03-23 BR BRPI0507999-3A patent/BRPI0507999A/pt not_active Application Discontinuation
- 2005-03-23 JP JP2007504474A patent/JP5016478B2/ja not_active Expired - Fee Related
- 2005-03-23 DK DK08157487T patent/DK1958633T3/da active
- 2005-03-23 AU AU2005225602A patent/AU2005225602A1/en not_active Abandoned
- 2005-03-23 PL PL08157487T patent/PL1958633T3/pl unknown
- 2005-03-23 PL PL05731809T patent/PL1729775T3/pl unknown
- 2005-03-23 EP EP20080157487 patent/EP1958633B1/de not_active Expired - Lifetime
- 2005-03-23 RS RSP20100217 patent/RS51306B/sr unknown
- 2005-03-23 CN CN2005800096821A patent/CN101022807B/zh not_active Expired - Fee Related
- 2005-03-23 HR HR20100287T patent/HRP20100287T1/hr unknown
-
2006
- 2006-09-25 IL IL178274A patent/IL178274A0/en unknown
-
2010
- 2010-05-21 CY CY101100456T patent/CY1110091T1/el unknown
-
2012
- 2012-03-14 CY CY20121100274T patent/CY1115040T1/el unknown
-
2014
- 2014-03-25 US US14/225,018 patent/US9024025B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110091T1 (el) | Διεργασια και ενδιαμεσες ενωσεις χρησιμες κατα την παρασκευη στατινων, ιδιαιτερα της ροσουβαστατινης | |
| GB0719180D0 (en) | New process | |
| DE602006009698D1 (de) | Verfahren zur herstellung von expoxybutanol-zwischenprodukten | |
| ATE377593T1 (de) | 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung | |
| ATE486857T1 (de) | Verfahren zur herstellung von telmisartan | |
| BRPI0409069A (pt) | compostos quìmicos | |
| ATE524505T1 (de) | Polymerisierbare zusammensetzung und flachdruckplattenvorläufer damit, alkalilösliches polyurethanharz sowie verfahren zur herstellung einer diolverbindung | |
| ATE372332T1 (de) | Verfahren zur herstellung von zwischenverbindungen in der herstellung von discodermolid und discodermolid-analoga | |
| DE502005008867D1 (de) | Verfahren zur herstellung von 2,5-dimethylphenylessigsäure | |
| ATE444323T1 (de) | Neuartige epoxidverbindungen und verfahren zu ihrer herstellung | |
| DE60040592D1 (de) | Verfahren zur herstellung von alpha-aminoketonen | |
| ATE364590T1 (de) | Verfahren zur herstellung von1-acetoxy-3- (substituiertes phenyl)propenen | |
| DE60141724D1 (de) | Methode zur Herstellung von Diazaphosphacyclen | |
| DE602006012622D1 (de) | Verfahren zur herstellung von 1,1,1-tris(4-hydroxyphenyl)alkanen | |
| ATE492523T1 (de) | Verfahren zur herstellung von halogensubstituiertem benzoldimethanol | |
| DE502005009657D1 (de) | Verfahren zur herstellung von substituierten thiophensulfonylisocyanaten | |
| DE602006008836D1 (de) | Reaktionsprodukt von Resorcin und Methylethylketon | |
| DK1598358T3 (da) | Forbindelser indeholdende 3,4-methylendioxythiophen-enheder | |
| WO2004091549A3 (en) | Process for making alpha-substituted hydroxamic acids | |
| DE502006002384D1 (de) | Verfahren zur herstellung von tetracarbonsäuren | |
| DE602004023633D1 (de) | Verfahren zur herstellung von 2,3,6,7,10,11-hexahydroxytriphenylen | |
| TW200720282A (en) | Novel organosilicon compound and process for producing the same | |
| ATE506349T1 (de) | Verfahren zur herstellung von 7-chinolinyl-3,5- dihydroxyhept-6-enoat | |
| ATE261950T1 (de) | Verfahren zur enantioselektiven herstellung von 3,3-diphenyl-2,3-epoxypropionsäureestern | |
| ATE516361T1 (de) | Verfahren zur herstellung eines carbonsäure- isomers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1729775 Country of ref document: EP |